Leuprol

Leuprorelin acetate, the active ingredient in Leuprol, is a gonadotropin‑releasing hormone (GnRH) agonist presented as an injectable solution for intramuscular or subcutaneous administration. It is used to manage hormone‑dependent conditions such as prostate cancer, endometriosis, precocious puberty, uterine fibroids, and as adjuvant therapy in certain breast cancer treatments.

GNH USA supplies Leuprol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, clinics and pharmacies worldwide, providing reliable access to this specialized hormone therapy through dedicated global robust quality systems.

Leuprol, a GnRH agonist, is used to modulate hormone‑driven disease pathways.

- Prostate cancer: lowers testosterone levels to slow tumor progression. - Endometriosis: suppresses estrogen production to reduce lesion growth and pain. - Precocious puberty: halts premature activation of the hypothalamic‑pituitary‑gonadal axis. - Uterine fibroids: diminishes estrogen‑driven fibroid enlargement. - Breast cancer (adjuvant): provides hormonal blockade to support other therapies. - Ovarian hyperstimulation syndrome: controls ovarian hormone surge during assisted reproduction.

Leuprol may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Injection site reactions: pain, redness or swelling at the site. - Headache: mild to moderate intensity. - Mood changes: irritability or depressive symptoms. - Decreased libido: reduced sexual desire. - Menstrual irregularities: spotting or amenorrhea.

Serious or Rare Side Effects: - Bone loss: increased risk of osteoporosis with long‑term use. - Cardiovascular events: rare cases of myocardial infarction or stroke. - Severe allergic reaction: anaphylaxis, angioedema or urticaria. - Pituitary apoplexy: sudden hemorrhage within the pituitary gland (extremely rare).

When prescribing Leuprol, several precautionary measures should be observed to ensure patient safety.

- Baseline hormone assessment: evaluate LH, FSH and sex steroid levels before initiation. - Bone health monitoring: perform periodic densitometry for patients on long‑term therapy. - Cardiovascular risk evaluation: assess history of heart disease or thromboembolic events. - Liver function: use caution in patients with hepatic impairment. - Hypersensitivity: avoid in individuals with known allergy to leuprorelin or formulation components. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Leuprol can interact with other medicines; awareness of these interactions helps to avoid complications.

Major Interactions (Avoid): - Concurrent GnRH antagonists or agonists: may cause excessive hormonal suppression. - Hormonal contraceptives: reduced efficacy, leading to unintended pregnancy.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): monitor INR as hormonal changes can affect clotting. - Glucocorticoids: increased risk of bone loss; consider calcium/vitamin D supplementation. - Antipsychotics that elevate prolactin: monitor for additive endocrine effects.